Research Papers:

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study

Carolina Sciortino, Valentina Viglialoro, Massimo Nucci, Mariam Grazia Polito, Enrico Cortesi, Alain Gelibter, Paola Gazzaniga, Chiara Nicolazzo, Marco Siringo and Salvatore Caponnetto _

PDF  |  Full Text  |  How to cite

Oncotarget. 2022; 13:686-693. https://doi.org/10.18632/oncotarget.28230

Metrics: PDF 650 views  |   Full Text 1091 views  |   ?  


Carolina Sciortino1, Valentina Viglialoro1, Massimo Nucci1, Mariam Grazia Polito1, Enrico Cortesi2, Alain Gelibter3, Paola Gazzaniga4, Chiara Nicolazzo4, Marco Siringo3 and Salvatore Caponnetto3

1 Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

2 Medical Oncology Unit B, Department of Radiological Oncological and Pathological Sciences, University La Sapienza, Rome, Italy

3 Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

4 Medical Oncology Unit, Department of Clinical and Molecular Medicine, Sapienza Università di Roma, Rome, Italy

Correspondence to:

Salvatore Caponnetto, email: [email protected]

Keywords: NSCLC; immunotherapy; KRAS G12C mutation; liquid biopsy

Received: March 11, 2022     Accepted: April 26, 2022     Published: May 11, 2022

Copyright: © 2022 Sciortino et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Non-small cell lung cancer is the leading cause of cancer death worldwide. New strategies in molecular therapies are being explored to detect and target genetic mutations in NSCLC. Therefore, it is also important to understand the interaction between these mutations and other therapies. This study focuses on possible correlations between the KRAS-G12C mutation and response of patients treated with immunotherapy.

Methods: Twenty-two patients with stage IV NSCLC undergoing immunotherapy were divided into two groups treated with first- and second-line therapy, respectively. KRAS-G12C mutation was detected by liquid biopsy Idylla KRAS assay.

Results: In first-line treated patients, there was no significant increase in PFS in patients with the KRAS mutation (20 months versus 14.5 months, HR = 1.31; CI 95% = 0.25–6.71; p value = 0.76) and no difference in OS (OS = 21 months, HR = 1; CI 95% = 0.17–6.2; p value > 0.99). In the second group, KRAS G12C mutated patients had a median PFS of 23 months compared with a median PFS of only 5 months among nonmutated patients (HR = 3.28; CI 95% = 0.86–12.5; p value = 0.03).

Conclusion: The results of this study do not reveal a clear correlation between mutation and response to immunotherapy. The mechanism regulating immune system activity in the tumor microenvironment remains unclear.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28230